

# Q1

## 1<sup>st</sup> Fiscal Quarter Financial results



"We are very pleased with the strong start to fiscal 2019. Together with Bard, we have a significant opportunity to deliver innovative healthcare solutions to our customers and their patients around the world. Our results reflect continued momentum across our businesses and regions, strong margin expansion, and excellent execution by our BD associates. Looking forward, I am confident that we will deliver on our commitments in fiscal year 2019 and beyond."

—Vince Forlenza, Chairman & CEO



**Q1 Revenue**  
**\$4.2B +5.2%<sup>1</sup>**



**Adjusted Q1 EPS<sup>2</sup>**  
**\$2.70 +14.9%**

Q1



**Medical**

**+5.2%<sup>1</sup>**



**Interventional**

**+5.7%<sup>1</sup>**



**Life Sciences**

**+4.7%<sup>1</sup>**

## Fiscal 2019 Guidance



Revenue<sup>1</sup>  
**+5.0% to +6.0%**



EPS<sup>2</sup>  
**\$12.05 to \$12.15**

(1) Reflects comparable revenue growth on a currency neutral basis, adjusted to include Bard, excludes divestitures, and reflects BD / Bard portfolio alignment.  
(2) Current and prior-year adjusted diluted earnings per share results exclude, among other things, the impact of purchase accounting adjustments (including the non-cash amortization of acquisition-related intangible assets); integration, and restructuring and transaction costs.

These materials also include Non-GAAP financial measures. A reconciliation to the comparable GAAP measures can be found in our earnings release and the financial schedules attached thereto.

A copy of our earnings release, including the financial schedules, is posted on the "Investors" section of the BD.com website.

This document contains forward-looking statements and it's possible that actual results could differ from our expectations. Factors that could cause such difference appear in our earnings release furnished as an exhibit to the Form 8-K that BD filed today with the SEC, and in our recent SEC filings.

